Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis.

Hebeisen, Monika; Scherer, Almut; Micheroli, Raphael; Nissen, Michael J; Tamborrini, Giorgio; Möller, Burkhard; Zufferey, Pascal; Exer, Pascale; Ciurea, Adrian (2019). Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis. PLoS ONE, 14(5), e0216746. Public Library of Science 10.1371/journal.pone.0216746

Preview

Text journal.pone.0216746.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (953kB) | Preview

OBJECTIVES

To compare drug survival in patients with axial spondyloarthritis treated with different TNF inhibitors in standard dosage.

METHODS

Patients fulfilling the Assessment in SpondyloArthritis international Society classification criteria for axial spondyloarthritis in the Swiss Clinical Quality Management cohort were included in this study if a first TNF inhibitor on standard dosage was started after recruitment and if a baseline visit was available. Drug maintenance up to drug discontinuation or dose escalation was compared between TNF inhibitors with multiple adjusted Cox proportional hazards models and multiple imputation for missing baseline covariate data.

RESULTS

A total of 966 patients were included (adalimumab 344, etanercept 237, golimumab 214, infliximab 171). Patients on certolizumab (n = 18) were excluded. Patients starting golimumab had lower disease activity as well as better physical function and quality of life in comparison to patients starting another drug. A higher proportion of patients starting infliximab had a history of extra-articular manifestations. Drug dosage was more often escalated during follow-up in patients treated with infliximab than with subcutaneously administered agents. However, no significant differences in time up to drug discontinuation or dose escalation were observed in multiple adjusted analyses if treatment was initiated after 2009, when all 4 TNF inhibitors were available: hazard ratio for infliximab versus etanercept 1.16 (95% confidence interval 0.80; 1.67), p = 0.44, for golimumab versus etanercept 0.80 (0.58; 1.10), p = 0.17 and for adalimumab versus etanercept 0.93 (0.69; 1.26), p = 0.66.

CONCLUSION

In axial spondyloarthritis, drug survival with standard doses of different TNF inhibitors is comparable.

Interest & Impact

Downloads

132 since deposited on 14 Jan 2020
19 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item